Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Final data from the phase 3b L-MOCA trial show that maintenance olaparib delivered a median overall survival of 51 months in Asian patients with platinum-sensitive, relapsed ovarian cancer. Patients with BRCA mutations fared even better, hitting a median OS of 64.4 months. The safety profile remained consistent with no new long-term signals identified after nearly six years of follow-up.
The final analysis of the phase 3b L-MOCA trial offers some of the longest follow-up data yet for olaparib (Lynparza) maintenance therapy in Asian patients with platinum-sensitive, relapsed ovarian cancer. After a median follow-up of 73.4 months across 224 patients treated at 37 centers in China and Malaysia, the results paint an encouraging picture — especially for patients with certain genetic profiles.
The overall population achieved a median OS of 51.0 months, but patients with BRCA-mutated disease pulled ahead significantly at 64.4 months, compared to 40.9 months for those with BRCA wild-type disease. Similarly, HRD-positive patients reached a median OS of 54.4 months versus 34.8 months for HRD-negative patients. On the safety front, while treatment-emergent adverse events were common (98.7%), no new long-term safety signals emerged, and the rate of serious late-onset hematologic malignancies (MDS/AML) remained low at 1.3%.
By the Numbers:
Why it matters: These long-term findings reinforce olaparib's role as a viable maintenance option for Asian patients with relapsed ovarian cancer, particularly those with BRCA mutations or HRD-positive disease. The data also provide reassurance on long-term safety — a key concern with PARP inhibitors — supporting their continued use in this population.
